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preoperative autologous donation, pharmaceuticals,
acute normovolemic hemodilution, cell salvage, and
intraoperative platelet-rich plasmapheresis. This last
technique involves the prebypass preparation of
platelet-rich plasma (PRP) from whole blood. Whereas
the separated red cells are readministered to the patient
before bypass, the PRP is given after the administration
of protamine. With some of the devices used for this
technology, the platelets may be concentrated further,
thus also allowing for retransfusion of platelet-poor
plasma before bypass. Both of these approaches spare
the platelets the potential detrimental effects of expo-
sure to the bypass circuit,1 which include a decrease in
the number of circulating platelets of up to 50% and
abnormal function in the remaining platelets.1
The primary objective of this meta-analysis was to
determine whether platelet-rich plasmapheresis in car-
C oncern about the side-effects of allogeneic bloodtransfusion, especially the transmission of viral
infections, has led to the development of a variety of
methods intended to minimize perioperative transfusion
in cardiac surgery. These include technologies such as
Objective: Our purpose was to determine whether intraoperative platelet-
rich plasmapheresis in cardiac surgery is effective in reducing the pro-
portion of patients exposed to allogeneic red cell transfusions. Methods:
A systematic search for prospective, randomized trials of platelet-rich
plasmapheresis in cardiac surgery, using MEDLINE, HEALTHSTAR,
Current Contents, “Biological Abstracts,” and EMBASE/Excerpta
Medica up to August 1997, was completed. Trials were included if they
reported either the proportion of patients exposed to allogeneic red cells
or the units of allogeneic red cells transfused. Trials were abstracted by
2 independent investigators and the quality of trial design was assessed
with the use of a validated scale. Results: Seventeen references met the
inclusion criteria (1369 patients [675 control: 694 platelet-rich plasma-
pheresis]). Platelet-rich plasmapheresis reduced the likelihood of expo-
sure to allogeneic red cells in cardiac surgery (odds ratio 0.44; 95% con-
fidence interval 0.27, 0.72, P = .001). Platelet-rich plasmapheresis had a
small but statistically significant effect on both the volume of blood lost
in the first 24 hours (weighted mean difference –102 mL; 95% confi-
dence interval –148, –55 mL, P < .0001) and the mean units transfused
(weighted mean difference –0.33 units; 95% confidence interval –0.43,
–0.23, P < .0001). However, platelet-rich plasmapheresis was only mar-
ginally effective (odds ratio 0.83, 95% confidence interval 0.34, 2.01, P =
.68) for “good” quality trials, whereas it appeared very effective in trials
with poor methodologic quality (odds ratio 0.33, 95% confidence inter-
val 0.17, 0.62, P = .0007). Conclusions: Although platelet-rich plasma-
pheresis appeared effective in decreasing the proportion of patients
receiving transfusions after cardiac operations, the quality of most of the
supporting trials was low and the benefit was small in trials of good
quality. Further clinical trials should be completed. (J Thorac
Cardiovasc Surg 1998;116:641-7)
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diac surgery is effective in reducing the proportion of
patients exposed to allogeneic red cells in the perioper-
ative period. The secondary objectives were to deter-
mine whether platelet-rich plasmapheresis is effective
in reducing the number of units of allogeneic red cells
transfused and the amount of blood lost during the first
24 hours after the operation. The impact of trial
methodology on efficacy was also assessed by means
of a validated quality assessment scale.2
Methods and materials
Literature search and study selection. Systematic searches
of MEDLINE (1966–July 1997), HEALTHSTAR (1995–July
1997), Current Contents (week 1–week 29, 1997), “Biologi-
cal Abstracts” (1990–March 1997), and EMBASE/Excerpta
Medica (1980-1997) were conducted in August 1997 to iden-
tify prospective randomized controlled trials. The search
strategy was first developed on MEDLINE and then adapted
to the controlled vocabulary of each of the other databases.3
All titles and abstracts of the identified articles were reviewed
by 2 investigators to determine potential eligibility for analy-
sis. Any trial comparing intraoperative platelet-rich plasma-
pheresis to an appropriate control group, regardless of lan-
guage or medium of publication, was retrieved for further
examination. Platelet-rich plasmapheresis was defined as the
process of preparation of autologous platelets from whole
blood by means of centrifugation. If insufficient detail was
provided in the abstract to determine eligibility, the article
was retrieved for further review. Medtronic Inc of Canada
(Mississaugua, Ontario) was asked to contribute all articles or
reports on this subject from their records. Bibliographies of
all identified trials and review articles were hand searched for
additional publications.
Authors of trials not reporting either the number of subjects
exposed to at least 1 unit of allogeneic red cells or the volume
of allogeneic red cells transfused were contacted in an
attempt to retrieve the necessary information. Duplicate pub-
lications, studies in children, and trials in which the patients
were pseudo-randomized were excluded.
Data extraction. Data from each of the studies were inde-
pendently abstracted onto study data forms by 2 individuals
(F.D.R., P.S.W.). Disagreements were resolved by consensus.
Non–English language trials were abstracted by 1 of the
investigators with the assistance of a translator. No attempt
was made to conceal the identity of the author or the medium
of the publication. When necessary, authors were contacted in
an attempt to clarify results or to provide missing data.
Data abstracted included the proportion of subjects
exposed to at least 1 unit of allogeneic red cells in the peri-
operative period, the type of operation (eg, primary versus
reoperative, valve versus coronary artery bypass grafting), the
mean units of packed red cells, platelets, and fresh frozen
plasma transfused per patient randomized, the mean blood
loss within 24 hours of the operation, whether a perioperative
transfusion protocol was reported, the preoperative use of
aspirin, the preoperative and discharge hematocrit values, and
the volume of PRP prepared. In those studies in which this
latter volume was recorded as a percentage of the total plas-
ma volume, a conversion factor of 45 mL/kg body weight was
used to estimate the total PRP collected.4 In 1 trial5 the vol-
ume collected was recorded in units of platelets. This was
converted to volume of PRP collected by means of a factor of
55 mL/unit (Clinical Guide to Transfusion; Canadian Red
Cross Society, 1987). The methodologic quality of the trials
was determined with the use of the scale developed by Jadad
and associates.2 This scale rates trial design from 0 to 5
depending on subject and investigator blinding, the method of
randomization, and the reporting of subject withdrawals. A
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Table I. Trial characteristics 
Postop 
First author Date Type of operation Procedure ASA preop transfusion threshold Jadad score
Boldt17 1990 Primary CABG No patients Yes 1
Jones18 1990 Primary CABG Some patients Yes 1
Boey14 1993 Primary CABG No patients Yes 2
Tobe15 1993 Primary CABG Some patients No 5
Boldt16 1993 Primary CABG No patients Yes 2
Ereth20 1993 Redo Valve Some patients Yes 3
Stammers21 1993 Primary and redo CABG and valve Some patients Yes 1
Wong13 1994 Primary CABG and valve Some patients Yes 2
Quigley10 1995 Primary CABG and valve Some patients Yes 1
Shore- Lesserson11 1995 Redo CABG and valve Some patients Yes 3
Armellin22 1995 Primary and redo CABG and valve No patients Yes 2
Triulzi12 1995 Primary and redo CABG and valve Some patients Yes 2
Christenson8 1996 Redo CABG Some patients Yes 1
Menges9 1996 Primary CABG No patients Yes 1
Stover5 1996 Primary and redo CABG and valve Data not given No 1
Armellin7 1997 Primary and redo CABG and valve Some patients Yes 3
Menges19 1997 Primary CABG No patients Yes 1
CABG, Coronary artery bypass grafting; redo, reoperative surgery.
score of 3 or more is considered good quality and a score of
less than 3 is considered poor quality.2
Analysis. The proportion of patients receiving a transfu-
sion was analyzed with Meta-Analyst (Meta-Analyst0.988;
Lau J, Chalmers TC, 1995) using Der Simonian and Laird’s
random effects model.6 Results are expressed as odds ratios
(OR) with 95% confidence intervals (95% CI). An OR of 1.0
suggests that there was no difference between treatment and
control, an OR less than 1.0 indicates that fewer patients in
the treatment group (PRP) received allogeneic red cell trans-
fusion, and an OR of greater than 1.0 indicates that more
patients in the treatment group received allogeneic red cell
transfusion. Tests for heterogeneity were performed for each
meta-analysis. If positive, the studies that appeared to be the
major contributors to the heterogeneity were evaluated in an
attempt to discover the possible reasons. Subgroup analyses
based on the type of procedure, volume of blood withdrawn
before the operation, transfusion protocol, and pretreatment
with aspirin were proposed a priori.
Continuous data, such as the total number of units of allo-
geneic red cells transfused and the mean blood loss during
the first 24 hours after the operation, were analyzed by means
of RevMan 1.04b (RevMan 1.04b, The Cochrane Review
Manager, 1994), which uses a fixed effects model. Summary
results of continuous data are expressed as weighted mean
differences (WMD) with 95% CI. 
Results
The systematic literature searches yielded 1072 refer-
ences in total. After review of all references, the bibli-
ographies of trials and reviews, and industry literature
searches, a total of 19 prospective randomized trials
were eligible for analysis. Of the 19 randomized con-
trolled trials, 1 was identified by industry5 and 18 were
identified by the systematic literature search. Whereas
17 met the inclusion criteria,5,7-22 information on out-
comes for 2 trials could not be obtained from either the
publication or communication with the authors.23,24 The
trials included in this meta-analysis included a total of
1369 patients (675 control patients; 694 patients sub-
jected to platelet-rich plasmapheresis). The characteris-
tics of the trials are summarized in Tables I and II.
Of the 17 included trials, 16 trials reported the pro-
portion of patients exposed to at least 1 unit of allo-
geneic red cells and 15 documented the total number of
units of allogeneic red cells transfused. The median
sample size of the 17 trials was 44 (range 24-284). The
mean volume of PRP collected was 730 mL (15 trials
reporting, range 306-1050 mL) and the mean 24-hour
blood loss was 821 mL in the platelet-rich plasma-
pheresis arm (12 trials reporting, range 481-1514 mL)
and 909 mL in the control arm (range 525-1304 mL).
The effectiveness of platelet-rich plasmapheresis on
the proportion of patients receiving allogeneic red cells
is shown in Fig 1. When all eligible trials were consid-
ered, platelet-rich plasmapheresis significantly reduced
the likelihood of exposure to at least 1 unit of allo-
geneic red cells (OR 0.44; 95% CI 0.27, 0.72; P =
.0012). Platelet-rich plasmapheresis reduced the num-
ber of units of allogeneic red cells transfused (WMD
–0.33 units; 95% CI –0.43, –0.23). Twelve of the stud-
ies provided sufficient information for the determina-
tion of the total 24-hour blood loss from the mediasti-
nal tubes. Platelet-rich plasmapheresis had a small but
statistically significant effect on the volume of blood
lost in the first 24 hours of the perioperative period
(WMD –102 mL; 95% CI –148, –55 mL; P = .00002).
Marked heterogeneity was found in the primary out-
come analysis of the proportion of patients receiving
allogeneic red cells (c 2 47.1; 15 degrees of freedom; P <
.001), as well as the secondary outcomes, 24-hour blood
loss (c 2 33.0; 11 degrees of freedom; P < .001), and
mean units transfused (c 2 61.2; 10 degrees of freedom;
P < .001).* Subgroups were analyzed to better clarify
the potential causes of this heterogeneity. The variables
examined in the subgroups were defined a priori and
included the surgical procedure, the proportion of
patients receiving acetylsalicylic acid, the transfusion
threshold, the amount of platelet plasma volume collected,
and the methodologic quality of the trials (Fig 2).
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*A c 2 for mean units could not be calculated for the 15 studies
because 4 studies had standard deviations of 0. Therefore a c 2 for
homogeneity was calculated for 11 studies.
Table II. Devices for collection of platelet-rich plas-
ma
First author Device*
Boldt16 Haemonetics Plasma Collecting System V50 
Jones18 Haemonetics Model 5000
Boey14 Haemonetics Plasma Collecting System
Tobe15 Haemonetics Plasma Saver Autologous 
Plasma Collection System
Boldt17 Haemonetics Plasma Collecting System V50
Ereth20 Haemonetics Plasma Saver
Stammers21 Haemonetics Plasma Saver
Wong13 Haemonetics Plasma Saver
Quigley10 Haemonetics Cell Saver IV
Shore-Lesserson11 Haemonetics Plasma Saver
Armellin7 Haemonetics Ultralite
Triulzi12 Haemonetics Plasma Saver
Christenson8 Electromedics Elmd—500 Autotransfusion/
Platelet Sequestration Device
Menges9 Haemonetics Plasma Collecting System V250
Stover5 Electromedics AT 1000
Armellin22 Haemonetics Ultralite
Menges19 Haemonetics
*Haemonetics Corporation, Braintree, Massachusetts. Electromedics Inc,
Parker, Colorado. 
For the primary outcome of the proportion of patients
receiving a transfusion of allogeneic red cells, there
was no evidence of a difference in efficacy among the
subgroups (Fig 2). There was a nonsignificant trend for
trials with poor methodology to yield larger effect
sizes. Additionally, there was a nonsignificant trend
toward trials with higher postoperative transfusion
thresholds and higher collected platelet plasma vol-
umes to demonstrate a smaller treatment effect.
Subgroup analysis was performed for mean units trans-
fused and the blood loss within 24 hours of the opera-
tion, and no differences were found that would explain
the heterogeneity (results not shown).
The rate of transfusion in the control group ranged
between 13% and 96% in patients undergoing cardiac
operations. Little correlation was observed between the
proportion of patients receiving an allogeneic transfu-
sion in the control group and the absolute risk reduction
caused by platelet-rich plasmapheresis (R2 = 0.0214).
Discussion
In this meta-analysis of patients undergoing cardiac
surgery, intraoperative platelet-rich plasmapheresis was
found to significantly decrease the proportion of
patients receiving a transfusion in the perioperative
period. Two secondary outcomes, mean units of allo-
geneic red cells transfused and mean blood loss within
24 hours of the operation, were also found to be signif-
icantly decreased in the experimental group compared
with the control group.
However, a marked heterogeneity was observed in
the results of the studies included in the meta-analysis.
Numerous subgroup analyses performed for all 3 out-
comes did not convincingly establish the reason for this
heterogeneity (Fig 2). Because of the significant unex-
plained heterogeneity, caution must be exercised in rec-
ommending this technology without further large,
high-quality randomized trials that clearly demonstrate
benefit. Furthermore, the only trial in this meta-analy-
sis that achieved a perfect methodologic score of 5 on
the Jadad scale had an OR of 1.02 (95% CI 0.31, 3.42),
which suggested that platelet-rich plasmapheresis was
not effective.15
It was puzzling to find that the efficacy of platelet-rich
plasmapheresis was inversely related to the volume of
platelets collected (Fig 3). However, several other
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Fig 1. Platelet-rich plasmapheresis in cardiac surgery: Proportion of patients receiving transfusions of allogeneic
red cells. CI, Confidence interval.
authors have already suggested that the most important
factor contributing to efficacy is the absolute number of
platelets collected, not their volume.25,26 In 2 of the tri-
als5,8 reported in this meta-analysis, in which between
300 and 350 mL of PRP was collected (OR 0.09; 95%
CI 0.01-0.9; P = .045), a 2-speed centrifugation tech-
nique was used (AT1000; Electromedics Inc, Parker,
Colo), which is known to produce a platelet-rich con-
centrate equivalent to 6 units of platelets.26 In 7 of the 17
trials, we were able to calculate, a posteriori, the number
of platelets extracted. There appeared to be a correlation
between efficacy and the number of platelets extracted,
although this correlation was not tested statistically (Fig 3).
This finding should be viewed with considerable caution
because this was a post hoc subgroup analysis conducted
on a small number of patients.27
Other factors may influence the efficacy of this tech-
nology. First, platelet function is significantly impaired
after centrifugation, and the platelets may be refractory
to stimulation for a period of 4 to 6 hours.28 Second,
although this technology decreased the volume of post-
operative shed mediastinal blood compared with that of
the control group (WMD –102 mL [–148, –55 mL]), it
cannot limit the intraoperative blood loss that occurs
during cardiopulmonary bypass. This loss is particularly
important with reoperative surgery because of vascular
adhesions and contributes to the increased transfusion
requirements in this population.
In the 1 trial that recorded complications related to
platelet-rich plasmapheresis,11 some of the patients had
hypotension and several had to be excluded from the
study before the completion of PRP collection as a result
of hemodynamic instability. This instability may have
been related to inadequate fluid replacement during the
withdrawal of whole blood, leading to hypovolemia.
Limitations of this meta-analyses must be addressed.
Caution must be exercised when looking at the results
of meta-analyses with small sample sizes. Meta-analy-
ses of other interventions, such as magnesium and
nitrates for patients with myocardial infarction, have
reached false positive conclusions about efficacy when
their results were compared with a subsequent “defini-
tive” large trial.29 Second, there was a large amount of
heterogeneity between the trials analyzed, which was
not explained by subgroup analyses. However, the lack
of an explanation may have been related to the fact that
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Fig 2. Proportion of patients receiving transfusions of allogeneic red cells: Subgroup analyses. CABG, Coronary
artery bypass grafting. ASA, acetylsalicylic acid; Hgb, hemoglobin; OR, odds ratio; CI, confidence interval; LL,
lower limit; UL, upper limit.
the subgroups were too small to allow statistically sig-
nificant answers to be found. Finally, not all studies
reported both the primary and secondary outcomes;
thus only a subset, albeit a majority of the identified tri-
als, were included in the analysis. Similarly, only a
handful of trials reported adverse events. This supports
the recommendations that uniform and comprehensive
standards are needed when reporting results of trials of
blood conservation technologies.30
In conclusion, the overall OR found in this meta-
analysis suggests that the proportion of patients receiv-
ing a transfusion was decreased in patients in whom
platelet-rich plasmapheresis was used in cardiac
surgery. This was associated with a decrease in the total
volume of transfused allogeneic red cells and a small
but statistically significant decrease in the total shed
mediastinal blood. However, the poor methodologic
quality of most of the trial reports and the marked het-
erogeneity of the results make it very difficult to deter-
mine the true efficacy of platelet-rich plasmapheresis.
A large, double-blind, randomized, controlled trial is
needed to further delineate the role of intraoperative
platelet-rich plasmapheresis in cardiac surgery.
We thank Dr. Howard Nathan for reviewing the manuscript,
as well as Drs. Tsuneo Ogawa and Ioulia Doumkina for their
assistance with translation.
R E F E R E N C E S
1. Campbell FW. The contribution of platelet dysfunction to post-
bypass bleeding. J Cardiothorac Vasc Anaesth 1991;5:8-12.
2. Jadad AR, Moore A, Carroll D, Jenkinson C, Reynolds DJM,
Gavaghan DJ. Assessing the quality of reports of randomized
clinical trials: Is blinding necessary? Control Clin Trials
1996;17:1-12.
3. Haynes RB, Wilcqynaski N, McKibbon KA, Walker CJ, Sinclair
JC. Developing optimal search strategies for detecting clinically
sound studies in MEDLINE. J Am Med Inform Assoc
1994;1:447-58.
4. Dacie JV, Lewis SM. Collection and handling of blood. In: Dacie
JV, Lewis SM, editors, Practical haematology, 7 ed. Edinburgh:
Churchill Livingstone; 1991. p. 1-7.
5. Stover EP, Siegel LC, Hood PA, O’Riordan GE. Platelet-rich
plasmapheresis with therapeutic platelet yield reduces allogeneic
red blood cell and platelet transfusions in high-risk cardiac
surgery [abstract]. Anesthesiology 1996;85.
6. Berlin JA, Laird NM, Sacks HS, Chalmers TC. A comparison of
statistical methods for combining event rates from clinical trials.
In: Anonymous statistics in medicine. John Wiley; 1989. p. 141-
51.
7. Armellin G, Sorbara C, Bonato R, Pittarello D, Dal Cero P, Giron
G. Intraoperative plasmapheresis in cardiac surgery. J Cardio-
thorac Vasc Anaesth 1997;11:13-7.
8. Christenson JT, Reuse J, Badel P, Simonet F, Schmuziger M.
Plateletpheresis before redo CABG diminishes excessive blood
transfusion. Ann Thorac Surg 1996;62:1373-9.
9. Menges T, Wagner RM, Welters I, Ruwoldt R, Boldt J,
Hempelmann G. The role of the protein C-Thrombomodulin sys-
tem and fibrinolysis during cardiovascular surgery: influence of
acute preoperative plasmapheresis. J Cardiothorac Vasc Anaesth
1996;10:482-9.
10. Quigley RL, Perkins JA, Caprini JA, et al. The haemostatic effec-
tiveness of autologous platelet rich plasma sequestered after
heparin administration and institution of cardiopulmonary
bypass. Perfusion 1995;10:101-10.
11. Shore-Lesserson L, Reich DL, DePerio M, Silvay G. Autologous
platelet-rich plasmapheresis: risk versus benefit in repeat cardiac
operations. Anesth Analg 1995;81:229-35.
12. Triulzi DJ, Gilmor GD, Ness PM, Baumgartner WA, Schultheis
LW. Efficacy of autologous fresh whole blood or platelet-rich
plasma in adult cardiac surgery. Transfusion 1995;35:627-34.
13. Wong CA, Franklin ML, Wade LD. Coagulation tests, blood loss,
and transfusion requirements in platelet-rich plasmapheresed ver-
sus nonpheresed cardiac surgery patients. Anesth Analg
1994;78:29-36.
14. Boey SK, Dhara SS. Preoperative plateletpheresis does not
reduce blood loss during cardiac surgery. Can J Anaesth
1993;40:844-50.
15. Tobe CE, Vocelka C, Sepulvada R, et al. Infusion of autologous
platelet rich plasma does not reduce blood loss and product use
after coronary artery bypass. Cardiovasc Surg 1993;105:1007-14.
16. Boldt J, Zickmann B, Ballesteros M, Oehmke S, Stertmann F,
Hempelmann G. Influence of acute preoperative plasmapheresis
on platelet function in cardiac surgery. J Cardiothorac Vasc
Anaesth 1993;7:4-9.
17. Boldt J, vonBormann B, Kling D, Jacobi M, Moosdorf R,
Hempelmann G. Preoperative plasmapheresis in patients under-
going cardiac surgery procedures. Anesthesiology 1990;72:282-8.
18. Jones JW, McCoy TA, Rawitscher RE, Lindsley DA. Effects of
646 Rubens et al The Journal of Thoracic and
Cardiovascular Surgery
October 1998
Fig 3. Effect size (proportion receiving allogeneic red cells)
versus total platelets extracted. CI, Confidence interval.
intraoperative plasmapheresis on blood loss in cardiac surgery.
Ann Thorac Surg 1990;49:585-90.
19. Menges T, Welters I, Wagner RM, Boldt J, Dapper F, Hempelmann
G. The influence of acute preoperative plasmapheresis on coagula-
tion tests, fibrinolysis, blood loss and transfusion requirements in
cardiac surgery. Eur J Cardiothorac Surg 1997;11:557-63.
20. Ereth MH, Oliver WC, Beynen FMK, et al. Autologous platelet-
rich plasma does not reduce transfusion of homologous blood
products in patients undergoing repeat valvular surgery.
Anesthesiology 1993;79:540-7.
21. Stammers AH, Kratz J, Johnson T, Crumbley J, Merrill J.
Hematological assessment of patients undergoing plasmapheresis
during cardiac surgery. J Extracorp Technol 1993;25:6-14.
22. Armellin G, Sorbara C, Bonato R, Pittarello D, Toniolo E, Giron
GP. Effects of acute intraoperative plasmapheresis in cardiac
surgery. Acta Anaesth Ital 1995;46:17-22.
23. Ferraris VA, Berry WR, Klingman RR. Comparison of blood
reinfusion techniques used during coronary artery bypass graft-
ing. Ann Thorac Surg 1993;56:433-40.
24. DelRossi AJ, Cernaianu AC, Vertrees RA, et al. Platelet-rich
plasma reduces postoperative blood loss after cardiopulmonary
bypass. J Thorac Cardiovasc Surg 1990;100:281-6.
25. Davies GG, Ruffcorn M, Dooley JB, Mabee TM, Sadler R,
Samelson S. Plateletpheresis before cardiopulmonary bypass. I.
Anesthesiology 1994;80:714.
26. Davies GG, Wells DG, Mabee TM, Sadler R, Melling NJ.
Platelet-leukocyte plasmapheresis attenuates the deleterious
effects of cardiopulmonary bypass. Ann Thorac Surg 1992;
53:274-7.
27. Oxman AD, Guyatt GH. A consumer’s guide to subgroup analy-
ses. Ann Intern Med 1992;116:78-84.
28. Gutensohn K, Bartsch N, Kuehnl P. Flow cytometric analysis of
platelet membrane antigens during and after continuous-flow
plateletpheresis. Transfusion 1997;37:809-15.
29. Brzak S, Ridker PM. Discordance between meta-analyses and
large-scale randomized, controlled trials. Ann Intern Med
1995;123:873-7.
30. Lemmer JH. Reporting the results of blood conservation studies:
the need for uniform and comprehensive methods. Ann Thorac
Surg 1994;58:1305-6.
The Journal of Thoracic and
Cardiovascular Surgery
Volume 116, Number 4
Rubens et al   647
Bound volumes available to subscribers
Bound volumes of The Journal of Thoracic and Cardiovascular Surgery are available to subscribers (only) for the 1998 issues from the
Publisher, at a cost of $122.00 for domestic, $151.94 for Canadian, and $142.00 for international subscribers for Vol 115 (January-June)
and Vol 116 (July-December). Shipping charges are included. Each bound volume contains a subject and author index and all advertising
is removed. Copies are shipped within 60 days after publication of the last issue of the volume. The binding is durable buckram with the
Journal name, volume number, and year stamped in gold on the spine. Payment must accompany all orders. Contact Mosby, Inc,
Subscription Services, 11830 Westline Industrial Drive, St Louis, MO 63146-3318, USA; phone 800-453-4351 or 314-453-4351.
Subscriptions must be in force to qualify. Bound volumes are not available in place of a regular Journal subscription.
